New drug aimed at making risky sickle cell cure more reliable
NCT ID NCT07252050
Summary
This study is testing if adding a drug called ruxolitinib to a stem cell transplant can make the procedure more successful for children and young adults with severe sickle cell disease. The main goal is to reduce the chance of the body rejecting the new cells (graft failure), which can cause the disease to return. Up to 24 participants will receive the treatment and be followed for two years to see if it improves survival without graft failure.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOETIC STEM CELL TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Healthcare of Atlanta
Atlanta, Georgia, 30329, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Children's Hospital of Colorado
Aurora, Colorado, 80045, United States
Contact
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
Contact
-
Manning Family Children's
New Orleans, Louisiana, 70118, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.